Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

Last updated July 6, 2022

Key Points

Key Points

This guideline update provides evidence-based recommendations to optimally use currently available biomarkers in the population of women presenting with early-stage breast cancer with known estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) status.

Diagnosis

...Diagnosis...

...Newly Diagnosed...

...Onc...

...mmendation 1.1If a patient has node...

...ion 1.2In the group of patients in Recommendatio...

...dation 1.3In the group of patients i...

...n 1.4If a patient is postmenopausal and has n...

...ecommendation 1.5In the group of patients...

...1.6If a patient is premenopausal and has node-...

...1.7If a patient has node-positive breast canc...

...MammaPrint (7...

...ion 1.8If a patient is older than 50...

...tion 1.9If a patient is 50 years of ag...

...ommendation 1.10If a patient has low clinical ri...

...ommendation 1.11If a patient has nod...

...EndoPredict (1...

...tion 1.12If a patient is postmenopausal and h...

...commendation 1.13If a patient is pr...

...n 1.14If a patient has breast cancer with more tha...

...Prosigna (PAM50)...

...mmendation 1.15If a patient is postmenopausa...

...1.16If a patient is premenopausal, and h...

Recommendation 1.17If a patient is postmenopa...

...dation 1.18If a patient has node-positi...

...here is insufficient evidence to recommend u...

...Breast Ca...

...f a patient has ER-positive, HER2-negative,...

...nt has ER-positive, HER2-negative, node-...

...Ki67...

...dation 1.19If a patient is postmenopausal an...

...ation 1.20If a patient is postmenopausal and has b...

...1.21Despite the limitations associated with Ki67...

...Immunohistochemist...

...on 1.22If a patient has node-negative or n...

...ient has ER-positive, HER2-negative (node-neg...

...ient has HER2-positive breast cancer or tripl...


...Extende...

...Oncotype DX,...

Recommendation 1.23If a patient has node-negative...

...BCI...

...1.24If a patient has node-negative or node-pos...

...ation 1.25If a patient has node-positive...

...Clinical Treatment...

...ation 1.26If a patient is postmenopausal and...


...HER2-positive Breast Ca...

...Oncotype DX,...

...mendation 1.27If a patient has HER2-po...


...Emerging Bioma...

...Tumor-Infiltrating L...

...on 1.28If a patient has node-negativ...

...PD-L1 Testin...

...mmendation 1.29If a patient has node-negative...

...C...

...ecommendation 1.30If a patient has node-...

...Circulati...

...ation 1.31If a patient has node-negative o...


...1. Breast Cancer Biomarkers to Guide Adjuvant Th...


...gorithm on Biomarkers to Guide Decisions on Adjuva...


...ble 2. Classification of Patients A...


...believes that cancer clinical tria...